Trader Joe's, Gerber and Texas Pete among FDA recalls for April 2025. See full list
Keeping up with FDA announcements about food and drug recalls can feel like a full-time job.
Here is what we know about what food and drugs were recalled in April.
The FDA removed the following items from store shelves in April:
Walker's Wine Juice LLC Pumpkin Juice: Recalled for potential Foodborne Illness - Botulism.
Panaderia/Bakery Quesadilla de Queso bread: Recalled for undeclared milk.
Tony's Chocolonely Inc. Dark Chocolate Almond Sea Salt Bar and Everything Bar: Recalled because the product may contain small stones.
Supercan pig ear silvers: Recalled for potential Salmonella contamination.
Texas Pete condiments: Contaminated products may contain Sriracha Sauce, which contains sulfites.
Caraluzzi's Italian Style Seafood Burgers: Recalled for undeclared egg.
Heinen's honey roasted peanuts: Recalled for undeclared cashews.
Marketside celery sticks: Recalled for listeria contamination.
Blue Ridge Beef Puppy Mix and Kitten Mix: Recalled for salmonella and listeria risk.
May Flower International soybean paste: Recalled for undeclared wheat.
Gerber Soothe N Chew teething sticks: Recalled and discontinued due to potential choking hazard.
Hofood99 Inc Enoki Mushrooms: Recalled for potential contamination with Listeria monocytogenes.
New England Village Snacks 19th Hole Snack Mix: Recalled for undeclared almonds.
Mauna Loa Dark Chocolate Covered Macadamias: Recalled for undeclared almonds and cashews.
Trader Joe's Sesame Miso Salad with Salmon: Recalled for undeclared milk allergen.
It's good to be aware if you recently purchased a recalled product. There are steps to follow if you do have these products in your home. According to FoodSafety.gov, here is what you should do.
Don't panic: The majority of food recalls are not directly linked to an outbreak of foodborne illness. Instead, many recalls are initiated due to the potential risk of contamination in the food product. In such cases, food manufacturers often issue a recall as a preventive measure to safeguard consumers.
Don't eat the food or consume the drug: To ensure your safety, refrain from consuming any recalled food products. Always prioritize caution over convenience. Additionally, please refrain from donating the recalled food to food banks or providing it to your pets, as they are also susceptible to food poisoning.
Don't open the food: To prevent foodborne illnesses, refrain from opening and inspecting food. Bacteria and viruses responsible for such illnesses are invisible, odorless, and tasteless. If you do handle the product, ensure you thoroughly cleanse your hands with warm water and soap for 20 seconds afterward.
Check the recall notice to find out what to do with the food: Upon a food product recall by a manufacturer, specific instructions are provided regarding the product's handling. These instructions generally entail one of the following actions: Return the product to the original store of purchase for a refund. Safely dispose of the product to prevent consumption by humans or animals, particularly if the product has been opened.
This article originally appeared on Austin American-Statesman: FDA recall list for April 2025: Gerber teething sticks, Texas Pete
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 hours ago
- Business Insider
Argenx presents new Efgartigimod data at EULAR 2025
argenx (ARGX) SE 'announced the presentation of positive results from Phase 2 studies evaluating VYVGART in Sjogren's disease and idiopathic inflammatory myopathies at the European Congress of Rheumatology, EULAR 2025, from June 11 – 14 in Barcelona, Spain. argenx also announced that the FDA has granted efgartigimod Fast Track designation for the treatment of primary Sjogren's disease.' Confident Investing Starts Here: Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
3 hours ago
- Yahoo
ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory
We came across a bullish thesis on ClearPoint Neuro, Inc. (CLPT) on M.V. Cunha's Substack. In this article, we will summarize the bulls' thesis on CLPT. ClearPoint Neuro, Inc. (CLPT)'s share was trading at $13.93 as of 6th June. A medical doctor surrounded by advanced technology in the operating room. ClearPoint Neuro is transforming from a surgical tools provider into a critical platform company enabling the next generation of neurological treatments. In the first quarter of 2025, revenue grew 31 percent year-over-year to 8.5 million dollars, led by the rapid adoption of its SmartFrame operating room system, which increased 70 percent and allows hospitals to use ClearPoint technology in standard surgical settings. This expansion seeds a larger installed base and drives high-margin recurring revenue from disposable instruments. The biologics and drug delivery segment generated 4.7 million dollars in revenue, growing 9 percent year-over-year, and is supported by more than 60 active partnerships with gene and cell therapy developers. As these therapies move toward commercial use, ClearPoint's role as the enabling delivery infrastructure could become its most profitable revenue stream, with each procedure generating over 20,000 dollars in high-margin recurring revenue. Meanwhile, the company is intentionally moving away from capital equipment sales, which declined 63 percent, in favor of a subscription-based model that provides predictable recurring revenue. Operating cash burn fell 35 percent in 2024, with expenses rising 29 percent in the latest quarter due to targeted investments in preclinical services, therapy support, and device innovation. ClearPoint closed the quarter with 12.4 million dollars in cash and access to up to 105 million dollars in financing, providing sufficient capital to reach financial breakeven without near-term equity dilution. While risks around execution, partner dependency, and regulatory pacing remain, ClearPoint's embedded position across neurological therapy development offers investors a unique opportunity to benefit from a long-term transformation into the backbone of next-generation brain treatments. Previously, we highlighted a on ClearPoint Neuro from northeasternsvf in January 2025, which emphasized its unique position as the only FDA-cleared, MRI-guided neurosurgical platform enabling precise delivery of CNS gene and cell therapies. That thesis focused on the company's expanding biopharma partnerships, operating room penetration through SmartFrame OR, and its path to profitability via high-margin disposables. ClearPoint Neuro, Inc. (CLPT) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held CLPT at the end of the first quarter which was 13 in the previous quarter. While we acknowledge the risk and potential of CLPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CLPT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Yahoo
7 hours ago
- Yahoo
Recall alert: Over 19,000 cans of Dr Pepper Zero Sugar recalled for containing sugar
Over 19,000 cases of Dr Pepper Zero Sugar are being recalled after the cans were found to contain full-sugar soda, the U.S. Food and Drug Administration announced. The voluntary recall issued on May 23 affects the 12-ounce aluminum cans of a 12-pack and 24-pack case of Dr Pepper Zero Sugar. 'Product labeled to be zero sugar contains full sugar product,' the FDA wrote about the drink. The recalled product contains the same amount of sugar found in regular Dr Pepper, which is 39 grams per can. The recalled cans have the product code XXXXRS05165 with a 'best by' date of February 16, 2026. The cans were made by Pepsi Beverages Company in Jacksonville, Florida and distributed to only Florida, Georgia and South Carolina. On June 5, the FDA then classified the product as a class II recall. This level of recall is 'a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote,' according to the FDA. See the full recall here. Recall alert: These window air conditioners could cause mold exposure Recall alert: Bring these crackers back to the store due to undeclared allergen Recall alert: Throw away these 17 salads, salsas due to salmonella concern Read the original article on MassLive.
